Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care
by
Braden Woodhouse 1
, Sharon Pattison 2, Eva Segelov 3, Simron Singh 4, Kate Parker 1, Grace Kong 5, William Macdonald 6, David Wyld 7,8, Goswin Meyer-Rochow 9, Nick Pavlakis 10, Siobhan Conroy 11, Vallerie Gordon 12, Jonathan Koea 13, Nicole Kramer 14, Michael Michael 15, Kate Wakelin 16, Tehmina Asif 17, Dorothy Lo 18, Timothy Price 19, Ben Lawrence 1,20,* and on behalf of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)
Braden Woodhouse 1, Sharon Pattison 2, Eva Segelov 3, Simron Singh 4, Kate Parker 1, Grace Kong 5, William Macdonald 6, David Wyld 7,8, Goswin Meyer-Rochow 9, Nick Pavlakis 10, Siobhan Conroy 11, Vallerie Gordon 12, Jonathan Koea 13, Nicole Kramer 14, Michael Michael 15, Kate Wakelin 16, Tehmina Asif 17, Dorothy Lo 18, Timothy Price 19, Ben Lawrence 1,20,* and on behalf of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)
1
Discipline of Oncology, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland 1023, New Zealand
2
Department of Medicine, University of Otago, Dunedin 9016, New Zealand
3
Department of Medical Oncology, Monash University and Monash Health, Melbourne 3800, Australia
4
Department of Medical Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, ON M4N 3M5, Canada
5
Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne 3000, Australia
6
Department of Nuclear Medicine, Fiona Stanley Hospital, Perth 6150, Australia
7
Department of Medical Oncology, Royal Brisbane and Women’s Hospital, Brisbane 4029, Australia
8
School of Medicine, University of Queensland, Brisbane 4072, Australia
9
Department of General Surgery, Waikato Hospital, Hamilton 3204, New Zealand
10
Department of Medical Oncology, Royal North Shore Hospital, Sydney 2065, Australia
11
Unicorn Foundation New Zealand, Auckland, New Zealand
12
Department of Medical Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada
13
Department of General Surgery, North Shore Hospital, Auckland 0620, New Zealand
14
Department of Pathology, North Shore Hospital, Auckland 0620, New Zealand
15
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia
16
Unicorn Foundation, Melbourne, Australia
17
Department of Medical Oncology, Saskatchewan Cancer Agency, Saskatoon, SK S4W 0G3, Canada
18
Department of Medical Oncology, St Joseph’s Health Care, Toronto, ON M6R 1B5, Canada
19
Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide 5011, Australia
20
Department of Medical Oncology, Auckland City Hospital, Auckland 1023, New Zealand
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(9), 1455; https://doi.org/10.3390/jcm8091455
Received: 31 July 2019 / Revised: 5 September 2019 / Accepted: 7 September 2019 / Published: 12 September 2019
(This article belongs to the Special Issue Advances in Diagnosis and Therapy of Neuroendocrine Neoplasms)
Quality performance indicators (QPIs) are used to monitor the delivery of cancer care. Neuroendocrine tumours (NETs) are a family of individually uncommon cancers that derive from neuroendocrine cells or their precursors, and can occur in most organs. There are currently no QPIs available for NETs and their heterogeneity makes QPI development difficult. CommNETs is a collaboration between NET clinicians, researchers and advocates in Canada, Australia and New Zealand. We created QPIs for NETs using a three-step consensus process. First, a multidisciplinary team used the nominal group technique to create candidates (n = 133) which were then curated into appropriateness statements (62 statements, 44 sub-statements). A two-stage modified RAND/UCLA Delphi consensus process was conducted: an online survey rated the statement appropriateness then the top-ranked statements (n = 20) were assessed in a face-to-face meeting. Finally, 10 QPIs met consensus criteria; documentation of primary site, proliferative index, differentiation, tumour board review, use of a structured pathology report, presence of distant metastasis, 5- and 10-year disease-free and overall survival. These NET QPIs will be trialed as a method to monitor and improve care for people with NETs and to facilitate international comparison.
View Full-Text
Keywords:
quality performance indicators; QPIs; cancer care; neuroendocrine tumour; NETs; modified Delphi; CommNETs
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Woodhouse, B.; Pattison, S.; Segelov, E.; Singh, S.; Parker, K.; Kong, G.; Macdonald, W.; Wyld, D.; Meyer-Rochow, G.; Pavlakis, N.; Conroy, S.; Gordon, V.; Koea, J.; Kramer, N.; Michael, M.; Wakelin, K.; Asif, T.; Lo, D.; Price, T.; Lawrence, B.; on behalf of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs). Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. J. Clin. Med. 2019, 8, 1455.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
- Supplementary File 1:
PDF-Document (PDF, 353 KB)
